Hipolabor Farmacêutica Ltda.

For more than four decades, Hipolabor Farmacêutica Ltda. has manufactured generic medicines for hospital and outpatient care, with injectable products at the center of its business. The company describes itself as Brazil’s largest manufacturer of injectable generics and ranked tenth among the nation’s generic drug manufacturers in the 2024 Anvisa Yearbook. Its portfolio comprises more than 100 registered medicines across injectable, solid, semi solid, and liquid dosage forms, serving demand for safe, effective, and accessible therapies.

Manufacturing and distribution are coordinated through two production plants and a storage center, employing more than 1,200 people. The Sabará plant, operating since 1988, produces semi solid, injectable, and liquid medicines. In Montes Claros, a 120,000 square metre manufacturing complex inaugurated in 2019 uses automated processes and advanced production equipment to expand capacity for generic medicines. Products undergo analysis and audits throughout manufacturing, with validated processes aligned with Brazilian National Health Surveillance Agency guidelines and national and international requirements for quality, safety, and efficacy.